Literature DB >> 2623081

Satiety in the obese Zucker rat: effects of carbohydrate type and acarbose (Bay g 5421).

C A Maggio1, J R Vasselli.   

Abstract

Despite the obese Zucker rat's hyperphagia on carbohydrate diets such as laboratory chow, this laboratory has found that its satiety response to glucose and other simple sugars is comparable to that of its lean control rat. To further investigate carbohydrate satiety in the Zucker rat, the short-term feeding behavior of obese and lean rats was observed following intragastric infusions (7.2 kcal in 10 ml) of corn starch and the starch hydrolysates Polycose and dextrin. There were no reliable between-genotype differences in the feeding inhibitory effects of Polycose and dextrin. However, in obese rats, the satiety effect of corn starch was delayed and reduced compared to that observed in lean rats (p less than 0.04). To modify the effect of corn starch, rats were administered 0.2 or 0.6 mg/infusion of the carbohydrate digestive inhibitor acarbose (Bay g 5421). Acarbose significantly reduced the satiety effect of corn starch in lean rats (p less than 0.001), and further attenuated satiety in obese rats (p less than 0.02). Since secretion of pancreatic amylase, the enzyme that initiates starch digestion, is decreased in obese rats, this result suggests that alterations of digestive and/or absorptive processes may underlie the obese rat's impaired satiety response to complex carbohydrate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2623081     DOI: 10.1016/0031-9384(89)90035-8

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  2 in total

1.  Acarbose treatment in obesity: a controlled study.

Authors:  F Bayraktar; F Hamulu; A G Ozgen; C Yilmaz; M Tüzün; T Kabalak
Journal:  Eat Weight Disord       Date:  1998-03       Impact factor: 4.652

Review 2.  A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus.

Authors:  F Santeusanio; P Compagnucci
Journal:  Drug Saf       Date:  1994-12       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.